ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...1213141516171819202122...129130»
  • ||||||||||  balstilimab (AGEN2034) / Agenus
    Phase classification, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases:  Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) -  Jan 10, 2023   
    P1/2,  N=41, Not yet recruiting, 
    Phase classification: P2 --> P1/2 | N=27 --> 41 | Trial completion date: May 2024 --> Sep 2026 | Initiation date: Sep 2022 --> Mar 2023 | Trial primary completion date: May 2024 --> Sep 2026
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Ivermectin for COVID-19: The 2022 Update. (Pubmed Central) -  Jan 7, 2023   
    After treatment with PYR, MBZ, ABZ, and IVM, it was determined that MBZ, ABZ, and IVM were efficacious against B. schroederi, while nematodes were suspected to be resistant to PYR according to the fecal egg count reduction (FECR) proportions. No abstract available
  • ||||||||||  ivermectin oral / Generic mfg., ivermectin topical / Generic mfg.
    Journal:  Gut microbiota of endangered Australian sea lion pups is unchanged by topical ivermectin treatment for endemic hookworm infection. (Pubmed Central) -  Jan 6, 2023   
    To our knowledge, this is the first study to characterise the gut microbiota of free-ranging Australian pinniped pups, compare the composition across multiple time points, and to consider the impact of parasitic treatment on overall diversity and microbial composition of the gut microbiota. Importantly, the lack of compositional changes in the gut microbiota with treatment support the utility of topical ivermectin as a safe and minimally invasive management strategy to enhance pup survival in this endangered species.
  • ||||||||||  long-acting injectable ivermectin / MedinCell
    Trial completion:  SAIVE: A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention (clinicaltrials.gov) -  Jan 6, 2023   
    P2,  N=400, Completed, 
    In this study ivermectin plus standard of care was not associated with improvement in the WHO-category ordinal scale, reduced illness duration, or development of severe COVID-19 in moderately ill COVID-19 patients. Recruiting --> Completed
  • ||||||||||  ivermectin oral / Generic mfg.
    AN UNUSUAL CASE OF PARASITIC CONSTRICTIVE PERICARDITIS (Complex Clinical Cases Moderated Poster Theater 5_Hall F) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_7381;    
    Parasitic pericarditis, although rare, should always considered as an etiology for pericarditis. Early diagnosis and treatment are the keys to prevent constriction.
  • ||||||||||  ivermectin oral / Generic mfg.
    A STRONG INFECTION AND A WEAK HEART (Poster Hall_Hall F) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_1721;    
    This case highlights a rare cause of eosinophilic myocarditis and describes successful treatment of this disease with rapid improvement in symptoms. It also highlights the limitations of a cardiac biopsy in the diagnosis of patchy processes like myocarditis.
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  Prospective mode of action of Ivermectin: SARS-CoV-2. (Pubmed Central) -  Jan 4, 2023   
    Present manuscript attempts to provide an overview of the detailed mechanism of action based on experimental and computational studies. The knowledge of binding interaction of IVM and SARS-CoV-2 targets will give the direction to developed new and potential anti-COVID agents.